18F-PSMA-1007 versus 18F-FDG PET/CT in the detection of hepatocellular carcinoma

作者：Xiaoli Mei, Yanpeng Li, Shasha Xu, Xiaoping Shang, Bing Cheng, Xiaobo Niu, Xiaoting Liu, Yan Liu, Xinya Cheng, Xingmin Han, Ruihua Wang · 发表于：Frontiers in Oncology · 年份：2025 · DOI：10.3389/fonc.2025.1711398 · 被引用次数：2 · 研究领域：Prostate Cancer Treatment and Research、Hepatocellular Carcinoma Treatment and Prognosis、Peptidase Inhibition and Analysis

Background Prostate-specific membrane antigen (PSMA) is expressed in hepatocellular carcinoma (HCC). Recently, 18 F-PSMA-1007 has been used for tumor imaging in positron emission tomography/computed tomography (PET/CT). This study aimed to compare the diagnostic performances of 18 F-PSMA-1007 PET/CT and 18 F-FDG PET/CT in HCC, and to assess factors associated with the sensitivity of 18 F-PSMA-1007 PET/CT in detecting HCC and intrahepatic tumor lesions. Materials and Methods Forty-four patients with suspected HCC undergoing both 18 F-FDG and 18 F-PSMA-1007 PET/CT were prospectively enrolled. Two experienced nuclear medicine physicians independently interpreted imaging results. The mean standardized uptake values (SUV mean ) were measured in the intrahepatic lesions (T), liver background (L), abdominal aorta (A), and right medial gluteal muscle (M), respectively. The tumor-to-background ratio (T/L, T/A, T/M) was then calculated as the SUV mean of the intrahepatic lesion (T) divided by the SUV mean of the background regions (L, A, M). Results Sixty-two intrahepatic lesions in 41 patients with HCC were finally involved in the statistical analysis. 18 F-PSMA-1007 PET/CT demonstrated higher sensitivity than 18 F-FDG PET/CT in detecting HCC patients (85.4% vs. 61.0%, P = 0.041), particularly in identifying well- or moderately differentiated HCC patients (92.9% vs. 14.3%, P = 0.003). 18 F-PSMA-1007 PET/CT showed a higher sensitivity than 18 F-FDG PET/CT in detecting intrahepatic HCC ...